Schizophrenia/Psychosis

A meta-analysis exploring factors associated with quality of life in first-episode psychosis provides guidance and take-home points for clinicians.

A clear problem creeping into the national dialogue is that patients with psychiatric issues all too frequently receive substandard medical care in the hospital setting. This points to the need to look for integrated approaches.

A novel compound holds promise for addressing cognitive deficits in schizophrenia.

The neuroprotective role of resilience in patients with schizophrenia who experienced early childhood trauma is evaluated in this brief update.

A multi-level, prevention-oriented approach that addresses poverty.

The release of the book described here comes amid a rising understanding that although we are 60 years into the antipsychotic era, these medications only partly help people with schizophrenia.

Handgrip is a simple proxy for muscular strength and a clinically useful measure of muscular function. What are the neurophysiologic underpinnings of the relationship between handgrip strength and cognition?

Negative symptoms identified from the Negative Symptom Assessment and the behaviors that might be observed in each of 5 domains.

With greater expertise in user experiences, psychiatrists can position themselves to more strongly guide technology companies in building and implementing better apps.

Handgrip is a simple proxy for physical strength and a clinically useful measure of muscular function. What about cognitive function in patients with schizophrenia? A large study looked into just that.

Might a lower prevalence suggest that it is less a problem?

Up to 50% of cases of cannabis-induced psychosis covert to schizophrenia. A new study provides striking evidence for abuse of other substances and schizophrenia onset.

Is there a link between childhood and parental asthma and risk of schizophrenia?

Are they hallucinations or distortions?

Here's a debate about a statistic the NIMH has posted on its website that, says one critic, significantly underestimates the number of adults with schizophrenia in the US and potentially affects their care. The Director of the NIMH responds.

The last major study of the prevalence of schizophrenia in the US was carried out in the early 1980s. The results from that study have been used for 3 decades.

A response from the NIMH director.

Anxiety and depression are associated with increased complications after total joint arthroplasty. Is the same true of bipolar and schizophrenic disorders?

An overview of the first study to demonstrate benefits of sodium benzoate--an NMDA enhancer--in patients with clozapine-resistant schizophrenia.

Functional connectivity is a “rapidly developing scientific story.” And for psychiatrists, it is a story worth following.

New research looks at the effects of CBD on positive and negative psychotic symptoms, cognitive performance, level of functioning, and the treating psychiatrist’s overall clinical impression.

Clinicians should be aware of recent research that highlights an important, although rare, adverse effect of this medication used to treat glaucoma.

Imagination and psychosis are different categories of experience, and should not be confused or conflated.

Is oxidative stress a therapeutic target in schizophrenia?

What the nose knows in patients with schizophrenia.